Ranevetmab

Ranevetmab_structure.png

Ranevetmab is a monoclonal antibody used in veterinary medicine for the management of pain associated with osteoarthritis in dogs. It is marketed under the trade name Librela.

Mechanism of Action

Ranevetmab is a monoclonal antibody that targets and neutralizes Nerve Growth Factor (NGF), a key mediator in the pain pathway. By inhibiting NGF, ranevetmab reduces pain signaling and inflammation, providing relief from chronic pain associated with osteoarthritis.

Clinical Use

Ranevetmab is administered via subcutaneous injection, typically on a monthly basis. It is specifically indicated for use in dogs suffering from osteoarthritis, a common condition that leads to joint pain and reduced mobility.

Efficacy

Clinical trials have demonstrated that ranevetmab significantly reduces pain and improves mobility in dogs with osteoarthritis. The treatment has been shown to be well-tolerated, with a safety profile comparable to placebo.

Safety and Side Effects

The most common side effects observed with ranevetmab are mild and include injection site reactions and transient lethargy. As with any therapeutic protein, there is a potential for immunogenicity, although this has been reported to be low in clinical studies.

Regulatory Status

Ranevetmab has been approved for veterinary use in several countries, including those in the European Union. It is not approved for use in humans.

Research and Development

Ranevetmab was developed as part of a growing interest in biologic therapies for chronic pain management in animals. Ongoing research is exploring the potential for similar therapies in other species and conditions.

Also see

• Monoclonal antibody therapy
• Osteoarthritis in dogs
• Nerve Growth Factor
• Veterinary medicine